Table 3.
PS-matched analysis of incident type 2 diabetes risk per treatment duration and SERM agent.
| Outcome | SERM Use | Non-Use | OR (95% CI) | p-Value |
|---|---|---|---|---|
| SERM agent | ||||
| Tamoxifen | 87/2185 (4.0) | 85/2185 (3.9) | 1.02 (0.76–1.39) | 0.88 |
| Toremifene | 25/346 (7.2) | 18/346 (5.2) | 1.42 (0.76–2.65) | 0.27 |
| Treatment duration (days) | ||||
| <600 | 32/808 (4.0) | 31/808 (3.8) | 1.03 (0.62–1.71) | 0.90 |
| 600 to <1500 | 40/934 (4.3) | 33/934 (3.5) | 1.22 (0.76–1.95) | 0.40 |
| ≥1500 | 40/789 (5.1) | 25/789 (3.2) | 1.63 (1.00–2.72) | 0.048 |
| Tamoxifen | 30/668 (4.5) | 25/789 (3.2) | 1.44 (0.84–2.47) | 0.19 |
| Toremifene | 10/121 (8.3) | 25/789 (3.2) | 2.75 (1.29–5.89) | 0.007 |
Notes: p-values were calculated with Chi-square test (Fisher’s exact test) for categorical variables. Statistically significant p-values are highlighted in bold. Abbreviations: PS, propensity score; SERM, selective estrogen receptor modulator; OR, odds ratio.